168 related articles for article (PubMed ID: 25961575)
1. The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014.
Brouard C; Le Strat Y; Larsen C; Jauffret-Roustide M; Lot F; Pillonel J
PLoS One; 2015; 10(5):e0126920. PubMed ID: 25961575
[TBL] [Abstract][Full Text] [Related]
2. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
Eckman MH; Ward JW; Sherman KE
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
[TBL] [Abstract][Full Text] [Related]
4. HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy.
Brouard C; Saboni L; Gautier A; Chevaliez S; Rahib D; Richard JB; Barin F; Larsen C; Sommen C; Pillonel J; Delarocque-Astagneau E; Lydié N; Lot F;
BMC Infect Dis; 2019 Oct; 19(1):896. PubMed ID: 31660879
[TBL] [Abstract][Full Text] [Related]
5. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
Deuffic-Burban S; Huneau A; Verleene A; Brouard C; Pillonel J; Le Strat Y; Cossais S; Roudot-Thoraval F; Canva V; Mathurin P; Dhumeaux D; Yazdanpanah Y
J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups.
Nakamura J; Terajima K; Aoyagi Y; Akazawa K
Tohoku J Exp Med; 2008 May; 215(1):33-42. PubMed ID: 18509233
[TBL] [Abstract][Full Text] [Related]
7. Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in France.
Loubière S; Rotily M; Moatti JP
Int J Technol Assess Health Care; 2003; 19(4):632-45. PubMed ID: 15095769
[TBL] [Abstract][Full Text] [Related]
8. 2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV.
Bottero J; Brouard C; Roudot-Thoraval F; Deuffic-Burban S; Hofliger P; Abergel A; Volant J; Dhumeaux D; Yazdanpanah Y;
Liver Int; 2016 Oct; 36(10):1442-9. PubMed ID: 27043826
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of hepatitis C infection, screening and associated factors among men who have sex with men attending gay venues: a cross-sectional survey (PREVAGAY), France, 2015.
Vaux S; Chevaliez S; Saboni L; Sauvage C; Sommen C; Barin F; Alexandre A; Jauffret-Roustide M; Lot F; Velter A;
BMC Infect Dis; 2019 Apr; 19(1):315. PubMed ID: 30971207
[TBL] [Abstract][Full Text] [Related]
10. Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States.
Barocas JA; Tasillo A; Eftekhari Yazdi G; Wang J; Vellozzi C; Hariri S; Isenhour C; Randall L; Ward JW; Mermin J; Salomon JA; Linas BP
Clin Infect Dis; 2018 Aug; 67(4):549-556. PubMed ID: 29420742
[TBL] [Abstract][Full Text] [Related]
11. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.
Ethgen O; Sanchez Gonzalez Y; Jeanblanc G; Duguet A; Misurski D; Juday T
J Med Econ; 2017 Feb; 20(2):162-170. PubMed ID: 27590836
[TBL] [Abstract][Full Text] [Related]
12. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
[TBL] [Abstract][Full Text] [Related]
13. HBV and HCV test uptake and correlates among men who have sex with men in China: a nationwide cross-sectional online survey.
Fitzpatrick T; Pan SW; Tang W; Guo W; Tucker JD
Sex Transm Infect; 2018 Nov; 94(7):502-507. PubMed ID: 29779005
[TBL] [Abstract][Full Text] [Related]
14. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk.
Litwin AH; Smith BD; Drainoni ML; McKee D; Gifford AL; Koppelman E; Christiansen CL; Weinbaum CM; Southern WN
Dig Liver Dis; 2012 Jun; 44(6):497-503. PubMed ID: 22342471
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.
Schackman BR; Gutkind S; Morgan JR; Leff JA; Behrends CN; Delucchi KL; McKnight C; Perlman DC; Masson CL; Linas BP
Drug Alcohol Depend; 2018 Apr; 185():411-420. PubMed ID: 29477574
[TBL] [Abstract][Full Text] [Related]
16. Routine screening for hepatitis C viral infection in patients undergoing elective cranial neurosurgery.
Nussbaum ES; Kallmes K; Lowary J; Nussbaum LA
J Neurosurg; 2018 Sep; 131(3):941-948. PubMed ID: 30215562
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study.
Semenova T; Nemoz B; Thibault V; Lagathu G; Duverlie G; Brochot E; Trimoulet P; Payan C; Vallet S; Henquell C; Chevaliez S; Bouvier-Alias M; Maylin S; Roque-Afonso AM; Izquierdo L; Lunel-Fabiani F; Marcellin P; Morand P; Leroy V; Larrat S
Epidemiol Infect; 2019 Jan; 147():e234. PubMed ID: 31364570
[TBL] [Abstract][Full Text] [Related]
18. The undiagnosed HIV epidemic in France and its implications for HIV screening strategies.
Supervie V; Ndawinz JD; Lodi S; Costagliola D
AIDS; 2014 Jul; 28(12):1797-804. PubMed ID: 24681416
[TBL] [Abstract][Full Text] [Related]
19. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
[TBL] [Abstract][Full Text] [Related]
20. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
McEwan P; Ward T; Yuan Y; Kim R; L'italien G
Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
